Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Extends Tender Offer for Spark Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
12/09/2019 | 02:02am EST

By Kim Richters

Roche Holding AG said Monday that it has extended the offer period for its planned takeover of biotechnology company Spark Therapeutics to Dec. 16.

Swiss pharmaceutical company Roche said the offer was extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their reviews of the pending acquisition.

The period for Roche's offer of $114.50 per share has been extended several times and was set to expire on Dec. 10.

As of Dec. 6, around 14.9% of Spark's outstanding shares had been tendered, according to Roche.

Write to Kim Richters at kim.richters@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG -3.95% 309.7 Delayed Quote.-1.37%
SPARK THERAPEUTICS, INC. 0.00%End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING AG
02/28UBS CEO's pay slips to $1 million a month as Swiss bank's top bosses pocket $..
RE
02/28ABBVIE : Venclexta Combination Study Didn't Meet Primary Endpoint
DJ
02/28Dicerna Announces Fourth Quarter and Full Year 2019 Financial Results and Pro..
AQ
02/28UBS CEO's pay slips to $1 million a month as Swiss bank's top bosses pocket $..
RE
02/28Biotech group Novacyt announces deals for coronavirus test product
RE
02/26ROCHE : Chemical reactions database updates to improve R&D information exchange
AQ
02/26BICYCLE THERAPEUTICS : Announces Exclusive Strategic Collaboration with Genentec..
AQ
02/26HALOZYME THERAPEUTICS : Announces FDA Has Accepted Biologics License Application..
AQ
02/26Bayer chairman quits as Roundup settlement talks progress
RE
02/26Bayer chairman quits as Roundup settlement talks progress
RE
More news
Financials (CHF)
Sales 2020 62 637 M
EBIT 2020 23 208 M
Net income 2020 15 243 M
Finance 2020 2 031 M
Yield 2020 3,03%
P/E ratio 2020 17,6x
P/E ratio 2021 16,6x
EV / Sales2020 4,17x
EV / Sales2021 3,93x
Capitalization 263 B
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 347,35  CHF
Last Close Price 309,70  CHF
Spread / Highest target 29,2%
Spread / Average Target 12,2%
Spread / Lowest Target -24,4%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-1.37%271 765
JOHNSON & JOHNSON-4.63%354 317
MERCK AND COMPANY-15.82%194 177
NOVARTIS-7.45%190 125
PFIZER, INC.-12.97%185 402
NOVO NORDISK AS6.69%136 811